Perspective Therapeutics, Inc.
CATX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CATX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CATX
Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using Lead-212 for cancers, with a theranostic approach combining imaging and treatment.
Key risk: Clinical-stage with no approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Perspective Therapeutics, Inc..
Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using Lead-212 for cancers, with a theranostic approach combining imaging and treatment.
- Proprietary technology uses the alpha-emitting isotope Lead-212 (212Pb) to deliver radiation specifically to cancer cells via specialized targeting moieties [sec_mda · as of 2026-03-16].
- Theranostic approach enables personalized treatment by using complementary imaging diagnostics with the same targeting moieties to visualize tumors before treatment [sec_mda · as of 2026-03-16].
- Cash and equivalents of $48.5M as of 2026-06-30, with a net loss of $26.8M for the period [sec].
- Believes cash resources are sufficient to fund current planned clinical milestones and operational investments into late 2027 [sec_mda · as of 2026-05-11].
- Pipeline includes Phase 1/2a trials for [212Pb]VMT-α-NET in neuroendocrine tumors and [212Pb]VMT01 in melanoma, and a Phase 1/2 trial for PSV359 in pancreatic ductal adenocarcinoma with FDA Fast Track designation [sec_mda · as of 2026-03-16][pipeline].
What works
- Proprietary Lead-212 alpha therapy platform offers a differentiated mechanism for targeted cancer cell killing, potentially improving efficacy and minimizing toxicity [sec_mda · as of 2026-03-16].
- Theranostic strategy (imaging + therapy) may enable patient selection and treatment optimization, a competitive advantage in radiopharmaceuticals [sec_mda · as of 2026-03-16].
- PSV359 for pancreatic ductal adenocarcinoma has received FDA Fast Track designation, potentially expediting development and review [sec_mda · as of 2026-03-16].
- Management expects current cash to fund operations into late 2027, providing a runway to advance key clinical milestones [sec_mda · as of 2026-05-11].
What to weigh
- Company is a clinical-stage biopharmaceutical firm with a limited operating history and no approved products, making investment highly speculative [sec_mda · as of 2026-03-16].
- Substantial additional capital will be required to fund operations, and future financing may be dilutive to shareholders or impose operational restrictions [sec_mda · as of 2026-03-16].
- Regulatory approvals are uncertain; the FDA may not grant or may delay approval for product candidates, and disruptions at the FDA could impact timelines [sec_mda · as of 2026-05-11].
- PSV359 faces a competitive landscape with multiple Phase 3 candidates from larger companies (e.g., Revolution Medicines, Arcus Biosciences) for pancreatic ductal adenocarcinoma [pipeline].
From the filings
Quoted directly from source documents.
Theranostic approach combines imaging and treatment
“We are also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes.”
SEC MD&A · March 16, 2026
Cash resources expected to fund operations into late 2027
“our belief regarding the sufficiency of our cash resources to fund our current planned clinical milestones and operational investments into late 2027”
SEC MD&A · May 11, 2026
PSV359 has FDA Fast Track designation
“our ability to obtain Fast Track designation from the U.S. Food and Drug Administration (FDA) under our Investigational New Drug application for our novel asset, PSV359”
SEC MD&A · March 16, 2026
Catalyst timeline
- 2023-06-01 · Phase 2 Start: A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dos - NCT: NCT05655312 — Trial for [212Pb]VMT01 in melanoma; status recruiting; endpoint is dose-limiting toxicities.
- 2023-09-27 · Phase 2 Start: A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced - NCT: NCT05636618 — Trial for [212Pb]VMT-α-NET in neuroendocrine tumors; status recruiting; endpoint is dose-limiting toxicities.
- 2025-04-28 · Phase 2 Start: A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb — Trial for PSV359 in pancreatic ductal adenocarcinoma; status recruiting.
Risks & what to watch (4)›
Key risks
- Clinical-stage with no approved products — Limited operating history and no approved products; investment is highly speculative [sec_mda · as of 2026-03-16].
- Need for substantial additional capital — Future financing may be dilutive or impose restrictions; cash runway only into late 2027 [sec_mda · as of 2026-05-11].
- Regulatory approval uncertainty — FDA may delay or deny approvals; disruptions at FDA could impact timelines [sec_mda · as of 2026-05-11].
- Competitive pressure in pancreatic cancer — PSV359 faces multiple Phase 3 competitors from larger firms [pipeline].
What to watch
- Interim data updates from Phase 1/2a trials of [212Pb]VMT-α-NET in neuroendocrine tumors and [212Pb]VMT01 in melanoma [sec · filed 2025-10-20].
- Progress of PSV359 Phase 1/2 trial in pancreatic ductal adenocarcinoma, including any regulatory milestones from Fast Track designation [sec_mda · as of 2026-03-16].
- Cash burn rate and any future financing activities, given the expectation that current cash funds operations into late 2027 [sec_mda · as of 2026-05-11].
- Manufacturing scale-up and expansion of the regional drug product finishing network [sec_mda · as of 2026-05-11].
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Perspective Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Perspective Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
33.2 months
D/E 0.21 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
135
Total value held
$317.4M
| Holder | Shares | Value |
|---|---|---|
| avidity partners management lp | 12,099,998 | $48.8M |
| vanguard capital management llc | 8,757,912 | $36.5M |
| commodore capital lp | 6,336,782 | $26.4M |
| blackrock, inc. | 5,348,561 | $22.3M |
| millennium management llc | 4,046,640 | $16.9M |
| citadel advisors llc | 3,640,204 | $15.2M |
| affinity asset advisors, llc | 3,164,582 | $13.2M |
| state street corp | 3,132,670 | $13.1M |
| balyasny asset management l.p. | 2,994,460 | $12.5M |
| morgan stanley | 2,983,342 | $12.4M |
Showing top 10 of 135 institutional holders of Perspective Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 13.6%
- Days to cover
- 11.1
- Shares short
- 12,997,351
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CATX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Perspective Therapeutics, Inc.?
Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using Lead-212 for cancers, with a theranostic approach combining imaging and treatment.
What is Perspective Therapeutics, Inc.'s lead drug candidate?
Perspective Therapeutics, Inc.'s most advanced tracked candidate is PSV359 (Phase 1/Phase 2) for Pancreatic Ductal Adenocarcinoma.
Who is the CEO of Perspective Therapeutics, Inc.?
Mr. Johan M. Spoor is the chief executive officer of Perspective Therapeutics, Inc. (CATX).
Where is Perspective Therapeutics, Inc. headquartered?
Perspective Therapeutics, Inc. (CATX) is headquartered in Seattle, WA, United States.
What therapeutic areas does Perspective Therapeutics, Inc. focus on?
Perspective Therapeutics, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.